- Home
- ABLV vs MAIA Comparison
ABLV vs MAIA Comparison
Compare ABLV & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ABLV | MAIA |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.1M | 44.9M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | ABLV | MAIA |
|---|---|---|
| Price | $0.83 | $1.26 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 945.8K |
| Earning Date | 12-30-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $114,319,869.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $17.33 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.59 | $0.87 |
| 52 Week High | $1.77 | $2.74 |
Technical Indicators
Market Signals| Indicator | ABLV | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 49.87 | 50.66 |
| Support Level | $0.74 | $1.13 |
| Resistance Level | $0.85 | $1.75 |
| Average True Range (ATR) | 0.13 | 0.16 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 22.83 | 25.00 |
Price Performance
Historical ComparisonAbout ABLV Able View Global Inc.
Able View Global Inc operates as a brand management partner of international beauty and personal care brands in China. It provides full-service solutions covering marketing plan, branding, digital and social marketing, omni-channel sales, customer service, overseas logistics, warehouse, and fulfillment. The firm generates revenue from product sales by distributing and selling cross-border products from various brand owners to Chinese consumers.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.